Stroke in Medical Technology

Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window

Findings May Potentially Lead to New Approach to Stroke Treatment BOCA RATON, Fla., July 30 /PRNewswire-USNewswire/ -- When minimally invasive endovascular (through the vessel) therapy made its debut two decades ago, stroke care underwent a major shift as the "window of treatmen...

D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients

REHOVOT, Israel, May 6 /PRNewswire/ -- D-Pharm announced today that it has submitted IND and Special Protocol Assessment (SPA) packages to the US Food and Drug Administration (FDA), for its pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients. D-Pharm plans to initiate ...

Statins Lower Stroke Severity, Improve Recovery

ROCHESTER, Minn., Feb. 26 /PRNewswire-USNewswire/ -- Mayo Clinic researchers have shown that patients who were taking statins before a stroke experienced better outcomes and recovery than patients who weren't on the drug -- even when their cholesterol levels were ideal. The finding is reported i...

Report on 300 New Medicines in Development for Heart Disease and Stroke Released in Indianapolis

INDIANAPOLIS, Feb. 26 /PRNewswire-USNewswire/ -- America's pharmaceutical research and biotechnology companies are testing a record number of potential medicines to treat two of the country's top killers. According to the latest report by the Pharmaceutical Research and Manufacturers of America (P...

Results of NeuroThera Effectiveness and Safety Trial - 2 (NEST-2) Presented at International Stroke Conference 2009

Encouraging Safety and Efficacy Results Support Follow-on NEST-3 Trial CARLSBAD, Calif., Feb. 20 /PRNewswire/ -- In a clinical trial sponsored by PhotoThera, Inc., transcranial laser therapy (TLT) for acute ischemic stroke within 24 hours of stroke onset demonstrated improved outcomes for pat...

AGA Medical Corporation Launches Web-Based Stroke Education and Awareness Program Featuring Professional Football Player Tedy Bruschi

MINNEAPOLIS, Jan. 29 /PRNewswire/ -- AGA Medical Corporation today launched a web-based stroke education and awareness program featuring Tedy Bruschi, a professional football player who suffered a stroke in February 2005, subsequently recovered and returned to his career. The unique online educati...

Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder

SAN FRANCISCO, Dec. 6 /PRNewswire-USNewswire/ -- A study assessing the quality of care for patients with sickle cell disease in a variety of hospital settings will be presented at a press conference on Saturday, December 6, at 9:30 a.m., during the 50th Annual Meeting of the American Society of He...

Portable CT Increases Chance of Stroke Survival and Recovery

CHICAGO, Dec. 2 /PRNewswire-USNewswire/ -- New research has found that the availability of a portable eight-slice computed tomography (CT) scanner in an emergency room can significantly increase the number of stroke victims who receive a potentially life-saving treatment. Results of the study, con...

ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin

LEUVEN, Belgium, September 29 /PRNewswire-FirstCall/ -- - Results Presented at World Stroke Congress in Vienna ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on novel therapies for eye disease, vascular disease and cancer, announces positive results from its MIT...

Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials

EMERYVILLE, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that previously found excess symptomatic intracranial hemorrhage in an earlier European trial of ancrod (now Viprinex(TM)) for the treatment of acute ischemic str...

Preliminary Data From Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa

BRIDGEWATER, N.J., Sept. 17 /PRNewswire/ -- Ortho Biotech has become aware of preliminary data from an investigator-initiated experimental study of the effects of Epoetin alfa in patients with acute ischemic stroke. In this study, patients suffering acute ischemic stroke who were treated with ...

Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation

This analysis showed that Multaq(R) (dronedarone) decreased the risk of stroke by 34% in patient with atrial fibrillation or atrial flutter already adequately treated by antithrombotic therapy BRIDGEWATER, N.J., Sept. 3 /PRNewswire-FirstCall/ -- The results of a post-hoc analysis ...

Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation

PARIS, September 3 /PRNewswire-FirstCall/ -- - This Analysis Showed That Multaq(R) (Dronedarone) Decreased the Risk of Stroke by 34% in Patients With Atrial Fibrillation or Atrial Flutter Already Adequately Treated by Antithrombotic Therapy The results of a post-hoc analysis of the data fr...

Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue

Could Be Life-Changing for Stroke, Traumatic Brain Injury, Alzheimer's Patients MORGANTOWN, W.Va., Sept. 1 /PRNewswire-USNewswire/ -- Scientists at the Blanchette Rockefeller Neurosciences Institute (BRNI) have discovered that Bryostatin -- and a related class o...

Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials

EMERYVILLE, Calif., Aug. 12 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that enrollment into its two Phase 3 pivotal studies evaluating Viprinex(TM) (ancrod) for the treatment of acute ischemic stroke has reached the level of patients ...

PRoFESS(R) Results Announced at XVII European Stroke Conference

RIDGEFIELD, Conn., May 14 /PRNewswire/ -- Results of the PRoFESS(R) (Prevention Regimen For Effectively avoiding Second Strokes) trial -- the world's largest clinical research study for secondary stroke prevention -- were presented today at the XVII European Stroke Conference in Nice, France. ...

Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference

NICE, France, May 14 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) reported for the first time at the European Stroke Conference detailed analyses supporting the dosing regimen in NTI's two ongoing Phase 3 studies of Viprinex(TM) (ancrod) for ischemic s...

Fifth DSMB Meeting Supports Neurobiological Technologies' Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)

EMERYVILLE, Calif., April 16 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today announced that after a scheduled review, an independent data safety monitoring board (DSMB) has recommended continuation of the company's two Phase 3 clinical trials to de...

International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery

SINGAPORE, Sept. 27 /Xinhua-PRNewswire/ -- NeuroAid(TM) is the first natural compound to be studied in a large clinical trial focused on stroke recovery starting in the acute stage. The CHIMES study is a multi-center double-blind placebo-controlled randomized trial to evaluate the efficacy of...

deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke

REYKJAVIK, Iceland, July 13 /PRNewswire-FirstCall/ -- Scientists at deCODE genetics (Nasdaq: DCGN ) and colleagues from Europe and the United States today report the discovery of a common single-letter variant in the sequence of the human genome (SNP) conferring increased risk of atrial fibr...

Atrial Fibrillation Found to be Common in Patients With Atherothrombosis, Increases Risk of Cardiovascular Death, Heart Attack and Stroke

TOKYO, November 7 /PRNewswire/ -- - Large, International REACH Registry Also Shows Many Patients With Atrial Fibrillation are Undertreated With Antiplatelet and Anticoagulant Therapies A significant portion of patients with atherothrombosis also have atrial fibrillation (AF), greatly incre...

ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ischemic Stroke

TUCSON, Ariz., Jan. 4 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX ) today provided an update on its TUCSON (Transcranial Ultrasound in Clinical SONolysis) clinical trial in patients with acute ischemic stroke. TUCSON Study Overview The TUCSON trial is a Phase I/II ran...

FASgen Announces New Discovery for Treatment of Stroke

BALTIMORE, Dec. 20 /PRNewswire/ -- FASgen is pleased to announce the recent publication of important results from research into a potential treatment for stroke using one of FASgen's proprietary compounds, C75. The Company is a leader in the research in the field of FASi (fatty acid synthase i...

Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke

SAN CARLOS, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO ) today announced dosing of the first patient in a Phase 2 proof-of-concept trial of alfimeprase for the treatment of acute ischemic stroke. Nuvelo has also been granted fast track designation by the U.S. Food ...

Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Pfizer announced today that Lipitor(R) (atorvastatin calcium) Tablets 10 mg provided a significant 61 percent reduction in stroke in patients with type 2 diabetes and metabolic syndrome but without heart disease. In a separate study, patients who had suf...

Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study

Independent Japanese study demonstrates dramatic benefits of adding Diovan to conventional therapy Study halted early due to superior outcomes for Diovan patients BASEL, Switzerland, April 27, 2007 - New findings from the independent Jikei Heart Study, published today in The Lanc...

Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study

Independent Japanese study demonstrates ...

Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)

Investigational Drug Being Pursued for the Treatment of Ischemic Stroke GLASGOW, Scotland, May 31, 2007 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI) announced today the presentation of new analysis of data from prior clinical trials of ancrod and updates on the clinical devel...

New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients

Aggrenox® (Asasantin® Retard) considered by many as first-line in secondary stroke prevention INGELHEIM, Germany, 31 May 2007 - New data presented today at the 16th European Stroke Conference in Glasgow confirm that therapy with dipyridamole plus ASA (extended-release dipyridamole plus...

Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - Pfizer announced today that Lipitor (atorvastatin calcium) Tablets 80 mg reduced the risk of stroke, coronary heart disease events and major coronary events in type 2 diabetes patients who had no known coronary heart disease but who had experienced a recent ...

Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke

EXACT and CAPTURE 2 Findings Suggest Improved Outcomes in Carotid Artery Stenting ABBOTT PARK, Ill., March 26, 2007 /PRNewswire-FirstCall/ -- Positive 30-day results from two Abbott studies confirm that carotid stenting can be performed with positive results by physicians with a variety of backgro...

Inotek Pharmaceuticals Announces Publication of Animal Data from Study of PARP Inhibition as Potential Preventative of Brain Injury Following Stroke

BEVERLY, Mass.--(BUSINESS WIRE)--Apr 10, 2007 - Inotek Pharmaceuticals Corporation announced today the publication in the journal Stroke of preclinical animal data showing that the administration of a poly(ADP-Ribose) polymerase (PARP) inhibitor has a large protective effect on the survival of cert...

The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke

Risk of Having a Venous ThromboEmbolism (VTE) is Reduced by a Significant 43% in Acute Ischemic Stroke Patients Treated With Clexane(R) / Lovenox(R) BRIDGEWATER, N.J., April 20, 2007 /PRNewswire-FirstCall/ -- Sanofi-aventis announced the publication of the PREVAIL (Prevention of VTE after Acute Is...

Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke

NICE Appraisal Committee concludes that alteplase is clinically and cost effective INGELHEIM/Germany, 14 May 2007 – A new clinical appraisal published by the National Institute for Health and Clinical Excellence (NICE) in the UK has recommended the use of alteplase for the treatment of...

Neurointerventionists Expand Research to Quality of Life in Aneurysm Patients Following Minimally Invasive Coiling Treatment

... have made numerous contributions to the neurosciences including: advancing stroke treatment through catheter based therapy; innovating endovascular coiling f...l procedures to treat fractures in the spine; and initiating the first-ever stroke registry to track procedural success in the treatment of acute stroke. More...

July 2009 Mayo Clinic Health Letter Highlights a Positive Outlook, Bell's Palsy and Heart Valve Repair

... treatment from a mental health professional to help shift to a more positive perspective. Bell's Palsy: Facial Paralysis That's Not a stroke ROCHESTER, Minn. -- Bell's palsy -- which causes sudden weakness or paralysis on one half of the face -- is not associated with stroke, and ...

Lupus Research Institute Highly Encouraged by Benlysta(TM) Trial Results

...d many currently used treatments are as toxic as the disease itself. Lupus is a leading cause of premature cardiovascular disease, kidney disease and stroke among young women. About the Lupus Research Institute Pioneering d iscovery to prevent, treat and cure lupus The Lup...

Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

... Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE-AF), is comparing edoxaban with warfarin (INR2-3) for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation. Edoxaban is also being studied for treatment of VTE, and for the prevention o...

Elbit Imaging Ltd. Announces - Swiss Team Uses InSightec's ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders

...urrounding tissue is spared. The ExAblate 4000 is a platform for a variety of transcranial indications, such as brain tumors, functional neurosurgery, stroke and targeted drug delivery. The ExAblate(R) 2000, based on the same technology, was approved by the U.S. Food and Drug Administration in 2004 a...

Dry Mouth Linked to Prescription and Over the Counter Drugs

...cluding HIV/AIDS, Alzheimer's disease, Sjogren's syndrome, anemia, rheumatoid arthritis, hypertension, diabetes, Parkinson's disease, cystic fibrosis, stroke and mumps. Certain cancer treatments, nerve damage, dehydration, smoking and chewing tobacco have also been connected with dry mouth. "It's not...